News by subject: TRI

Constant Therapeutics LLC, a biopharmaceutical company focused on the development of treatments impacting the Alternative Renin-Angiotensin System, today announced that the first patient was dosed March 3, 2024, in the Company's phase 2 clinical...

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced two posters in Parkinson's disease (PD) will be shared at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2024), being held in Lisbon, Portugal, and virtually,...

WCG, the global leader in providing solutions that measurably improve and accelerate clinical research, announces the expansion of its capabilities with the introduction of Statistical Consulting Solutions. Developed to combat some of the pervasive...

IceCure Medical Ltd. ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that results from an...

Valo Health, Inc (Valo), a technology company focused on utilizing large scale data and artificial intelligence (AI) driven computation to discover and develop therapeutics, today announced full enrollment in the company's Phase 2 Spectra clinical...

Marks a major step in the development of what could be the first drug approved for Suicidal Bipolar DepressionThe study database is being cleaned and locked; statistical analysis and top-line data to follow shortly thereafterStudy maintained 95%...

Neurocode USA, Inc, a specialized clinical laboratory that offers world-class testing solutions for neurological disorders, is pleased to announce the clinical launch of ALZpath Dx, an innovative and novel blood test that can be used in the...

Berlin Cures, a clinical-stage...

Fauna Bio, biotechnology company improving human health by leveraging animal genomics, announced today Dr. Lara Do Amaral-Silva, assistant professor of biology at Wake Forest University, as the recipient of the FaunaBio Translational Research Award...

QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that will alter the trajectory of amyotrophic...

Avidity accelerates global Phase 3 HARBORtm study initiation to Q2 2024 following regulatory agreement on study design; primary endpoint is video hand opening time (vHOT) and secondary endpoints include muscle strength and activities of daily living...

YolTech Therapeutics, a biotech company developing in vivo gene editing therapies to treat rare genetic diseases, today announced the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has officially  approved the...

BD (Becton, Dickinson and Company) , a leading global medical technology company, today announced the enrollment of the first patient in the investigational device exemption (IDE) study, "AGILITY," which will assess the safety and effectiveness of...

MGI Tech, a company committed to building core tools and technology to lead life science, today proudly announced a milestone collaboration with Eurofins Genomics Europe Genotyping A/S ("Eurofins Genomics"), which has placed a corporate order of the...

The European Society of Gynecological Oncology (ESGO) 2024 Conference has recently made selected abstracts available online. The abstract (abstract # 251) that details results from the Phase II clinical trial (DUBHE-C-206) evaluating the efficacy and...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced dosing of the first patient in the STARLIGHTtm 2 Phase 3 pivotal study for fezolinetant, an investigational oral, nonhormonal compound being studied for...

Caliway Biopharmaceuticals (Caliway) announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to CBL-514 for Dercum's disease treatment. CBL-514 is a lipolysis injection that can reduce local subcutaneous fat...

Mezzion Pharmaceuticals is a rare disease company conducting the confirmatory pivotal phase 3 clinical trial in Fontan subjects: The Fontan Udenafil Exercise Longitudinal Assessment Trial- 2, or FUEL-2 trial. The company is pleased to announce Dr....

Aadi Bioscience, Inc. , a biopharmaceutical company focused on developing and...

Approval is based on results from the Phase 3 PAPILLON study, which demonstrated RYBREVANT® plus chemotherapy reduced the risk of disease progression or death by 61 percent versus chemotherapy alone in patients with previously untreated NSCLC with...

NeuroKey-3tm measures key biomarkers implicated in neurodegeneration, covering multiple aspects of Alzheimer's Disease and Dementia pathology, including neuroinflammation (IL-18), synaptic degeneration (NRGN), neurotrophic factor (BDNF), and...

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of five abstracts in amyotrophic lateral sclerosis (ALS) at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held in Orlando, Fla.,...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that today the National Medical Products Administration...

Kinnate has entered into an Asset Purchase Agreement (the "APA") with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.The transaction is in furtherance of Kinnate's previously announced pursuit of strategic...

Boston Scientific Corporation today announced it has received U.S. Food and Drug Administration (FDA) approval for the AGENTtm Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery...

Jacobio Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced it received IND (Investigational New Drug) approval of its self-developed drug JAB-30300 (P53 Y220C activator) from the FDA of the U.S....

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major...

Pedaling on a stationary bicycle built for two may improve the health and well-being for both people with Parkinson's disease and their care partners, according to a small, preliminary study released February 29, 2024, that will be presented at the...

REGENXBIO Inc. today announced that it will host a live webcast to discuss new interim clinical data from the Phase I/II AFFINITY DUCHENNE® trial of RGX-202...

As reported in today's issue of the journal Metabolites, researchers at Metabolomycs, a California-based biotechnology company, for the first time applied targeted mass spectrometry to show that pancreatic cancer arises through changes in cellular...

Spatz Medical, a global leader in gastrointestinal weight loss solutions, is delighted to announce the commencement of commercialization of the Spatz3 Adjustable Gastric Balloon. With over 150,000 patients benefiting from the Spatz3 across more than...

US patients are willing to share their health data across clinical trials studies, offering the potential for global biopharma organizations to radically increase the pace of R&D, according to new data from PA Consulting (PA), the company that's...

Today, researchers at Vivacelle Bio, Inc., a pioneering biotechnology company revealed the compelling outcomes of their phase 2a clinical trial of the investigational cardiovascular support fluid, VBI-S, in patients with severe septic shock. This...

Headlands Research, a leading multinational network of clinical trial sites, today announced the acquisition of Pharmasite Research, an established clinical trial site dedicated to research in mental illness and disorders of the central nervous...

LISCure Biosciences, a leading clinical-stage biopharmaceutical company focused on discovering and developing innovative microbiome-based therapies, announces the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug...

Perimeter Medical Imaging AI, Inc. ("Perimeter" or the "Company") ? a commercial-stage medical technology company ? announced results from a peer-reviewed retrospective study1 examining the integration of Wide Field Optical Coherence Tomography...

Indo US Organization for Rare Diseases (IndoUSrare) has always been a steadfast ally to rare disease patients, and Rare Disease Day 2024 will be no exception. Beyond honoring these individuals on February 29 through online and in-person events,...

NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it has received first site Institutional Review Board (IRB) approval for Alexander Prezioso, M.D.,...

Immunic, Inc. , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the presentation of data from the company's phase 2 CALLIPER and...

Spineart SA, manufacturer of the BAGUERA®C Cervical Disc Prosthesis, is delighted to announce completion of enrollment in its U.S. IDE trial studying the BAGUERA®C Cervical Disc Prosthesis in patients with single-level cervical disc disease between...

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, is pleased to announce that it has received approval from the UK's Medicines and...

CalciMedica Inc. (CalciMedica or the Company) , a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases,...

Koning Health, a pioneering medical imaging company, is thrilled to announce that it has received regulatory clearance from the Federal Authority for Nuclear Regulation (FANR) in the United Arab Emirates (UAE), marking a significant milestone in the...

BlueWind Medical, Ltd. today announced that Dr. Osvaldo Padron of Florida Urology Partners in Tampa, Florida, has treated the first patient in the RESTORE study, a prospective, multi-center, open label, post market, randomized controlled trial. The...

Head and neck squamous cell carcinoma (HNSCC) is a type of cancer that affects the mucous membranes of the mouth, nose, and throat. HNSCC is typically associated with tobacco exposure, alcohol abuse, and viral infections. The links between human...

The Lupus Research Alliance (LRA) is pleased to announce the recent recipients of the Lupus Mechanisms and Targets Award (LMTA), whose research will investigate molecular pathways or targets that will lead to new or improved therapies for individuals...

Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule RNA splicing modifiers, today...

Highlights: Monepantel displays a superior safety, tolerability to the leading FDA approved drug Relyvrio®Preliminary efficacy data shows a 58% reduction in the rate of disease progression for Cohort 2 (High Dose) using the FDA primary efficacy...

ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR)...

On an Intent-to-Treat Analysis, Co-Primary Symptom Endpoint Met, Statistical Significance (P<0.025)Multiple Secondary Symptom Endpoints Met, Statistical Significance (P<0.025)On an Intent-to-Treat Analysis, Co-Primary Sign Endpoint and...